BRIEF—Huadong intends to withdraw from vTv collab

A  licensing agreement between vTv Therapeutics and Huadong Pharmaceutical will be scrapped, after the latter stated its intent to withdraw from the deal, a  filing with the US SEC reveals.

vTv had granted Huadong an exclusive license in China and certain other countries, including Australia and South Korea, for patent rights and know-how related to the GLP-1 agonist TTP273.

Huadong has indicated that it intends to discontinue further development of TTP273.

The termination will be effective once both parties negotiate and finalize an agreement.